Coherent Biopharma Ltd, a Suzhou-based specialist in bispecific-ligand drug conjugates (Bi-XDC), has reportedly raised an undisclosed amount in a Series B financing round. The funding was led by HM Capital and included participation from Suzhou Yuanfeng Capital, ABC International, V-Capital, and existing investor 6 Dimensions Capital.
Company Profile
Coherent Biopharma leverages its BEST, C-PROTAC, and chronic disease technology platforms to develop innovative therapies. Its lead candidate, CBP-1008, is in a Phase I clinical trial with promising dose-escalation data and is expected to advance to pivotal Phase II trials by year-end. Another candidate, CBP-1019, is on track for Investigational New Drug (IND) filings in China and the U.S. within 2023.
Funding Use
Proceeds from the Series B round will support clinical trials for CBP-1018 and CBP-1019, as well as an IND filing for CBP-8088 (C-PROTAC). The funding will accelerate Coherent Biopharma’s efforts to advance its Bi-XDC pipeline.-Fineline Info & Tech
